Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Trends of antimicrobial resistance of Gram-positive and Gram-negative bacteria.

From: Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital

  Number of resistant isolates/total isolates tested (proportion) within the year
Microorganisms 2002 2003 2004 2 005 2002/2003 2004/2005 p-value**
Gram-positive        
Staphylococcus epidermidis        
Oxacillin 171/202 (84.7) 215/261 (82.4) 179/219 (81.2) 75/94 (79.8) 386/463 (83.3%) 254/313 (81.2%) 0.10
Gentamicin 144/202 (71.3) 168/261 (64.4) 148/219 (67.6) 54/94 (57.5) 312/463 (67.4%) 202/313 (64.5%) 0.37
Vancomycin 0/202 (0) 0/261 (0) 0/219 (0) 0/94 (0) 0/463 (0%) 0/313 (0%) NA
Staphylococcus aureus        
Oxacillin 25/38 (65.8) 21/30 (70) 12/25 (48) 6/8 (75) 46/68 (67.6%) 18/33 (54.5%) 0.19
Gentamicin 23/38 (60.5) 4/30 (13.3) 6/25(24) 3/8 (37.5) 27/68 (39.7%) 9/33 (27.3%) 0.22
Vancomycin 0/38 (0) 0/30 (0) 0/25 (0) 0/8 (0) 0/68 (0%) 0/33 (0%) 1
Enterococcus faecalis        
Vancomycin 0/14 (0) 2/19 (10.5) 0/7 (0) 0/4 (0) 2/33 (6.1%) 0/11 (0%) 1
Enterococcus faecium        
Vancomycin 1/15 (6.7) 0/8 (0) 3/11 (27.3) 0/2 (0) 1/22 (4.5%) 3/13 (23.1%) 0.13
Gram negative        
Acinetobacter baumannii        
Amikacin 6/9 (66.6) 10/15 (66.6) 32/35 (91.4) 15/17 (88.2) 16/24 (66.7%) 47/52 (90.4%) 0.019
Ceftazidime 8/9 (88.8) 13/15 (86.6) 34/35 (97.1) 17/17 (100) 21/24 (87.5%) 51/52 (98.1%) 0.09
Ciprofloxacin 6/9 (66.6) 11/15 (73.3) 34/35 (97.1) 17/17 (100) 17/24 (70.8%) 51/52 (98.1%) 0.001
Colistin 1/9 (11.1) 0/15 (0) 0/35 (0) 1/17 (5.8) 0/24 (0%) 1/52 (0%) 1
Gentamicin 4/9 (44.4) 10/15 (66.6) 16/35 (45.7) 12/17 (70.5) 14/24 (58.3%) 28/52 (53.8%) 0.71
Imipenem 4/9 (44.4) 8/15 (53.3) 34/35 (97.1) 17/17 (100) 12/24 (50%) 51/52 (98.1%) <0.001
Piperacillin/Tazobactam 7/9 (77.7) 12/15 (80) 34/35 (97.1) 17/17 (100) 19/24 (79.2%) 51/52 (98.1%) 0.01
Pseudomonas aeruginosa        
Amikacin 15/32 (46.9) 15/33 (45.5) 17/25 (68) 4/11 (36.4) 30/65 (46.2%) 21/36 (58.3%) 0.24
Ceftazidime 18/32 (56.3) 19/33 (57.6) 21/25 (84) 8/11 (72.7) 37/65 (56.9%) 29/36 (80.6%) 0.016
Ciprofloxacin 20/32 (62.5) 14/33 (42.4) 17/25 (68) 5/11 (45.4) 34/65 (52.3%) 22/36 (61.1%) 0.39
Colistin 0/32 (0) 0/33 (0) 0/25 (0) 0/11 (0) 0/65 (0%) 0/36 (0%) 1
Imipenem 20/32 (62.5) 14/33 (42.4) 15/25 (60) 5/11 (45.4) 34/65 (52.3%) 20/36 (55.5%) 0.75
Piperacillin/Tazobactam 3/32 (9.4) 7/33 (21.2) 18/25 (72) 2/11 (18.2) 10/65 (15.4%) 20/36 (55.5%) 0.10
Klebsiella pneumoniae        
Ceftazidime 2/7 (28.6) 11/34 (32.4) 15/29 (51.7) 9/11 (81.8) 13/41 (31.7%) 24/40 (60%) 0.010
Ciprofloxacin 1/7 (14.3) 12/34 (35.3) 16/29 (55.2) 4/11 (36.4) 13/41 (31.7%) 20/40 (50%) 0.006
Meropenem 0/7 (0) 1/34 (2.9) 8/29 (27.6) 9/11 (81.8) 1/41 (2.4%) 17/40 (42.5%) <0.001
Cefepime 0/7 (0) 11/34 (32.4) 15/29 (51.7) 9/11 (81.8) 11/41 (26.8%) 24/40 (60%) <0.001
Cefoxitin 0/7 (0) 10/34 (29.4) 18/29 (62.1) 9/11 (81.8) 10/41 (24.4%) 27/40 (67.5%) <0.001
Tobramycin 0/7 (0) 8/34 (23.5) 17/29 (58.6) 9/11 (81.8) 8/41 (19.5%) 26/40 (65%) <0.001
Piperacillin/Tazobactam 0/7 (0) 8/34 (23.5) 15/29 (51.7) 9/11 (81.8) 8/41 (19.5%) 24/40 (60%) <0.001
Escherichia coli        
Amikacin 0/35 (0) 0/57 (0) 4/47(8.5) 1/30(0) 0/92 (0%) 5/77 (6.5%) 0.05
Ciprofloxacin 7/35 (0.2) 3/57 (5.2) 4/47(8.5) 9/30(30) 10/92 (10.9%) 13/77 (16.9%) 0.006
Piperacillin/Tazobactam 1/35 (2.8) 1/57 (1.7) 4/47(8.5) 2/30(6.6) 2/92 (2.2%) 6/77 (7.8%) 0.37
Ceftazidime 2/35 (5.7) 0/57 (0) 4/47(8.5) 5/30(16.6) 2/92 (2.2%) 9/77 (11.7%) 0.02
Cefoxitin 4/35 (11.4) 1/57 (1.7) 4/47(8.5) 4/30(13.3) 5/92 (5.4%) 8/77 (10.4%) 0.18
Meropenem 1/35 (2.8) 0/57 (0) 1/47(2.1) 0/30(0) 1/92 (1.1%) 1/77 (1.3%) 0.52
  1. * Data for the year 2005 refer to the period from January 2005 through June 2005.
  2. ** P-values refer to the comparison of proportions between 2002/2003 and 2004/2005.